CNK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CNK is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to act now. The stock has supportive analyst sentiment, improving box office expectations, and a favorable SwingMax entry signal from May 18, but the current setup is not strong enough to call it a direct buy: insiders are selling heavily, the latest quarter was still lossmaking, and the shares are already near short-term resistance. My direct view is hold rather than buy today.
CNK is in a mild bullish short-term trend. MACD histogram is positive and expanding, which supports upward momentum, while RSI at 60.16 is neutral-to-slightly bullish and not overbought. Moving averages are converging, suggesting the trend is improving but not strongly trending yet. Price at 27.38 is just above pivot 26.73 and below resistance 27.48, so the stock is pressing into a near-term ceiling. This is constructive, but not a decisive breakout setup.
Analysts have been steadily lifting price targets, with JPMorgan, Wells Fargo, Roth Capital, Morgan Stanley, and B. Riley all raising targets recently. The news flow points to stronger box office conditions, with better-than-expected Q1 box office and expectations for an improved 2026 and 2027 film slate. Hedge funds are buying aggressively, with buying up 101.37% last quarter. The company also reported 18.9% revenue growth year over year, and attendance around 39 million shows demand is recovering. SwingMax gave an entry signal on 2026-05-18, which supports the bullish setup.
Insiders are selling heavily, with selling up 2039.74% over the last month, which is the biggest negative signal in the dataset. Helix Partners fully exited its stake by selling 300,000 shares. The latest quarter still showed a net loss of $6.4 million, so profitability is not fully back yet. The stock is close to resistance, limiting immediate upside from a fresh entry.
Latest reported quarter: revenue rose 18.9% year over year to $643.1 million, which is a strong growth trend for the latest quarter. However, Cinemark still posted a net loss of $6.4 million, so top-line momentum is improving faster than bottom-line earnings. Attendance of about 39 million reinforces that the recovery is being driven by healthier theater traffic. Since the latest quarter season is Q1 2026, the business is showing recovery, but not yet consistent earnings strength.
Analyst sentiment is positive overall. Recent target increases from JPMorgan, Morgan Stanley, Roth Capital, B. Riley, and Wells Fargo show rising confidence in Cinemark's recovery and box office leverage. The ratings mix is constructive: JPMorgan and Wells Fargo are Overweight, Roth is Buy, while Morgan Stanley is only Equal Weight and B. Riley is Neutral, which shows some caution on valuation and industry box office assumptions. Wall Street's pros see box office recovery, margin expansion, and higher free cash flow; the main con is valuation and uncertainty around box office consensus.
